Open AccessUse of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria
Author(s) -
Sydney E. Liang,
Rachel Hoffmann,
Erik Peterson,
Nicholas A. Soter
Publication year - 2018
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2018.3715
Subject(s) - dapsone , medicine , dermatology , retrospective cohort study , surgery
The first-line treatment for patients with chronic spontaneous urticaria (CSU), which is divided into idiopathic and autoimmune subtypes, consists of H1-antihistamines. However, limited evidence guides the treatment of CSU after maximal therapy with antihistamines fails. Two randomized clinical trials suggest that dapsone may be a successful second-line therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom